Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment

CLARITY Extension data published in the MS Journal shows 75% of patients who received 2 annual short courses of Mavenclad (Cladribine Tablets) remained relapse free over 4 years The majority of patients who experienced Grade 3 lymphopenia in Years 1 and... Biopharmaceuticals, Neurology Merck, MAVENCLAD, Cladribine, multiple sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news